<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Quick reference for evaluation and management of COVID-19-associated hypercoagulability</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Quick reference for evaluation and management of COVID-19-associated hypercoagulability</h1>
<div class="graphic"><div class="figure"><div class="ttl">Quick reference for evaluation and management of COVID-19-associated hypercoagulability</div><div class="cntnt"><table cellspacing="0"><colgroup width="15%"></colgroup> <colgroup width="85%"></colgroup> <tbody> <tr> <td class="subtitle1_left" colspan="2">Evaluations and monitoring</td> </tr> <tr> <td class="indent1">Inpatients</td> <td> <ul> <li>Initial PT, aPTT, fibrinogen, D-dimer; frequency of monitoring depends on acuity and trend in values</li> <li>Diagnostic imaging studies if feasible for clinically suspected DVT or PE; consult PERT team</li> <li>Alternative evaluations if standard imaging studies are not feasible</li> </ul> </td> </tr> <tr> <td class="indent1">Outpatients</td> <td> <ul> <li>Routine coagulation testing is not required</li> </ul> </td> </tr> <tr> <td class="subtitle1_left" colspan="2">Management</td> </tr> <tr> <td class="indent1">Abnormal coagulation studies</td> <td> <ul> <li>Use for prognostic information and level of care</li> <li>Do not intervene solely based on coagulation abnormalities</li> </ul> </td> </tr> <tr> <td class="indent1">VTE prophylaxis</td> <td> <ul> <li>Individualized risk-benefit assessment to determine dosing; prophylactic dosing preferred for ICU patients; therapeutic dosing preferred for non-ICU inpatients</li> <li>Dose adjustments may be made for increased body weight or decreased kidney function</li> <li>LMW heparin is generally preferred over other anticoagulants</li> <li>Thromboprophylaxis is generally not continued following discharge, with rare exceptions</li> <li>Thromboprophylaxis is generally not used in outpatients, with rare exceptions</li> </ul> </td> </tr> <tr> <td class="indent1">VTE treatment</td> <td> <ul> <li>Therapeutic (full-dose) anticoagulation for documented VTE or high suspicion for VTE <ul> <li>Initiate in hospital per standard protocols</li> <li>Continue for at least 3 months</li> <li>Unfractionated heparin preferred for unstable patients with organ dysfunction</li> <li>LMW heparin or a DOAC (apixaban or rivaroxaban) can be used for stable patients without organ dysfunction</li> </ul> </li> <li>Reserve fibrinolytic agents (eg, tPA) for limb-threatening DVT, massive PE, acute stroke, or acute MI; consult PERT or stroke team</li> </ul> </td> </tr> <tr> <td class="indent1">Clotting in vascular catheters or extracorporeal circuits*</td> <td> <ul> <li>Therapeutic (full-dose) anticoagulation</li> <li>Standard protocols for continuous renal replacement therapy or ECMO</li> </ul> </td> </tr> <tr> <td class="indent1">Bleeding</td> <td> <ul> <li>Similar to individuals without COVID-19 <ul> <li>Transfusions for anemia or thrombocytopenia using appropriate transfusion thresholds</li> <li>Anticoagulant reversal and/or discontinuation for anticoagulant-associated bleeding</li> <li>Specific treatments (eg, factor replacement) for underlying bleeding disorders</li> </ul> </li> <li>Avoid antifibrinolytic agents in individuals with acute decompensated DIC<sup>¶</sup></li> </ul> </td> </tr> </tbody></table></div><div class="graphic_lgnd">Refer to UpToDate for discussions of COVID-19 management. Resources are also available from the International Society on Thrombosis and Haemostasis (<a href="https://onlinelibrary.wiley.com/doi/10.1111/jth.14853" target="_blank">https://onlinelibrary.wiley.com/doi/10.1111/jth.14853</a>), the American Society of Hematology (<a href="https://www.hematology.org/covid-19/covid-19-and-coagulopathy" target="_blank">https://www.hematology.org/covid-19/covid-19-and-coagulopathy</a>), and the American College of Cardiology (<a href="https://www.acc.org/latest-in-cardiology/articles/2020/04/17/14/42/thrombosis-and-coronavirus-disease-2019-covid-19-faqs-for-current-practice" target="_blank">https://www.acc.org/latest-in-cardiology/articles/2020/04/17/14/42/thrombosis-and-coronavirus-disease-2019-covid-19-faqs-for-current-practice</a>).</div><div class="graphic_footnotes"><p>COVID-19: coronavirus disease 2019; PT: prothrombin time; aPTT: activated partial thromboplastin time; DVT: deep vein thrombosis; PE: pulmonary embolism; PERT: pulmonary embolism response team; VTE: venous thromboembolism; ICU: intensive care unit; tPA: tissue plasminogen activator; MI: myocardial infarction; ECMO: extracorporeal membrane oxygenation; DIC: disseminated intravascular coagulation.</p>
<p>* Includes continuous renal replacement therapy (hemodialysis), ECMO, or other extracorporeal circuits.</p>
	
	¶ Acute decompensated DIC is associated with clinical bleeding and/or thrombosis and laboratory findings including prolonged PT and aPTT, thrombocytopenia, and hypofibrinogenemia. Antifibrinolytic agents (tranexamic acid and epsilon aminocaproic acid) are avoided because they may tip the balance towards thrombosis. Refer to UpToDate for details.</div><div id="graphicVersion">Graphic 127960 Version 5.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
